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Myxoid Chondrosarcoma of the Phalanx
with an EWS Translocation
A Case Report and Review of the Literature
By David B. Bumpass, MD, Michael Kyriakos, MD, David A. Rubin, MD, Paul R. Manske, MD, and Charles A. Goldfarb, MD
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M

yxoid chondrosarcoma is a histologically and genetically distinct tumor that predominantly originates
in soft tissue, unlike conventional chondrosarcoma,
which arises primarily in bone 1-3. Several hundred cases of
extraskeletal myxoid chondrosarcoma have been reported, but
true intraosseous myxoid chondrosarcoma tumors have rarely
been reported. Several nonrandom chromosomal translocations, most commonly t(9;22) EWS-CHN, have been identified
in extraskeletal myxoid chondrosarcoma4,5. These translocations can help with diagnosis; however, to date, no such
translocation has been identified in an unequivocal skeletal
myxoid chondrosarcoma tumor, leading previous authors to
conclude that skeletal and extraskeletal myxoid chondrosarcoma tumors are separate and distinct entities6,7. We present the
case of a patient with myxoid chondrosarcoma with both a
clear skeletal origin and an EWS-containing chromosomal
translocation, thus providing evidence that the skeletal and
extraskeletal forms of myxoid chondrosarcoma represent the
same pathologic entity. The patient was informed that data
concerning the case would be submitted for publication, and
she consented.

Case Report
nineteen-year-old woman presented with a nine-month
history of a progressively enlarging, painful mass of the
right long finger. There was no history of trauma or foreignbody penetration. She had no constitutional symptoms, and the
medical history was remarkable only for asthma. On examination, there was a 2 · 1.5 · 1.5-cm mass involving the middle
phalanx (Fig. 1). There was decreased active digital flexion,
mild ulnar deviation of the finger, and normal sensation. The
patient had no antecubital or axillary lymphadenopathy.
Radiographs demonstrated a lytic expansile lesion of the
middle phalanx of the long finger (Figs. 2-A and 2-B). No fullthickness cortical destruction was evident, although the ex-

tensive endosteal scalloping made this difficult to confirm. The
lesion extended to the proximal articular surface, where a
pathologic fracture was noted. The proximal and distal interphalangeal joints were unaffected. No matrix formation was
visible. Magnetic resonance imaging (MRI) studies showed a
marrow-replacing lesion filling the entire middle phalanx that
was hyperintense compared with skeletal muscle on watersensitive images (Figs. 3-A and 3-B). No soft-tissue extension
was visible.
On the basis of the benign radiographic assessment, an
excisional biopsy was planned. At surgery, there was extensive
bone destruction and only a thin, incomplete portion of dorsal
cortex and several small areas of articular cartilage at the
proximal and distal interphalangeal joints were intact. We
performed an intralesional excision with attempted preservation of the articular surfaces and as much of the middle phalanx

A

Fig. 1

Photograph demonstrating a mass in the middle phalanx of the long finger.
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Fig. 2-B

Anteroposterior (Fig. 2-A) and lateral (Fig. 2-B) radiographs of the long finger, showing a lytic, expansile lesion involving the
majority of the middle phalanx, without visible internal matrix. Note the pathologic fracture (arrow) of the proximal articular
surface.

as possible. No soft-tissue component was evident. A cortical
strut graft together with cancellous bone graft harvested from a
clean surgical field of the distal end of the radius was used to
reconstruct the middle phalanx.

Fig. 3-A

Grossly, the excised tissue had a lobulated, gelatinous
consistency without evident calcification. Histologically, the
tumor was composed of small epithelioid-like cells, with densely
eosinophilic cytoplasm, arranged in strands, cords, and small

Fig. 3-B

T2-weighted coronal spin-echo (Fig. 3-A) and T2-weighted sagittal gradient (Fig. 3-B) magnetic resonance images demonstrating a hyperintense, marrow-replacing lesion contained within the expanded
middle phalanx. There is no associated macroscopic soft-tissue extension.
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Fig. 4

Low-power (left) and higher-power (right) photomicrographs of the tumor show bland-appearing small
cells arranged in cords and strands, separated by an abundant blue-gray myxoid stroma.

nests within an abundant blue-gray myxoid stroma (Fig. 4). In
most of the tumor, the cells had mildly atypical nuclei with a
uniform chromatin pattern. However, in some foci, the nuclei
were enlarged with moderate atypia and prominent nucleoli.
Scattered cells containing densely eosinophilic globular cyto-

plasmic inclusions that distorted and compressed the nuclei,
creating the appearance of rhabdoid cells, were also found (Fig.
5). Mitotic figures were noted, with as many as four per highpowered field. No evidence of cartilage, chondroid tissue, or
cells in lacunar spaces was found.

Fig. 5

High-power photomicrographs showing most tumor cells to have small, oval to round nuclei, with a
small nucleolus and a uniform chromatin pattern. Among these cells are scattered larger rhabdoid
cells (arrows) that contain dense eosinophilic cytoplasmic inclusions compressing dense, hyperchromatic nuclei (left). Focal areas of the tumor contain larger, epithelioid-like cells with prominent
nucleoli and dense eosinophilic cytoplasm (right).
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Fig. 6

Break-apart fluorescence in situ hybridization (FISH) study, with use of EWS (22q12) probe, showing
several tumor cell nuclei (arrows) with widely separated red and green signals indicating the
presence of an EWS-containing chromosomal translocation.

Histochemical studies showed the myxoid stroma to be
strongly stained by alcian blue at both pH 1.0 and 2.5, with the
staining being resistant to change by pretreatment of the tissue
sections with bovine testicular hyaluronidase. The stroma also
yielded a metachromatic reaction with toluidine blue. Immunostaining showed diffuse and strong tumor cell reactivity
for vimentin, neuron-specific enolase, chromogranin, and synaptophysin, with retention of nuclear reactivity for the INI-1
gene product with use of BAF47 antibody. Immunostaining for
S-100 protein and epithelial membrane antigen were only
weakly and focally positive, while that for cytokeratin (AE1/
AE3) was negative.
With use of paraffin sections of formalin-fixed tumor
tissue, a fluorescence in situ hybridization (FISH) study with a
commercial Ewing sarcoma (EWS, 22q12) break-apart probe
(Vysis, Downers Grove, Illinois) showed widely separated red
and green signals found in two-thirds of 200 counted interphase tumor cells (Fig. 6). This finding is consistent with the
presence of the EWS-containing chromosomal translocation
typically seen in extraskeletal myxoid chondrosarcoma4. On the
basis of the results of the various tissue studies, a diagnosis of
skeletal myxoid chondrosarcoma was made.
After the diagnosis, a computed tomography scan of the
chest and a bone scan were performed to evaluate for metastatic disease. Both were negative. The patient underwent a ray
resection of the long finger without transposition seventeen
days after the initial procedure. Histologic analysis of the amputation specimen showed only a solitary microfocus of a few
residual tumor cells within the periosteal soft tissue adjacent to

the middle phalanx; resection margins were otherwise free of
tumor. One year postoperatively, the patient was healthy with
an aesthetically acceptable hand and full finger flexion.
Discussion
n review of the English-language literature, we found
forty-six possible cases of skeletal myxoid chondrosarcoma6-27. Thirty-two cases fit our inclusion criteria of clear
intraosseous origin with reliable pathologic and radiographic
diagnosis10,13,14,16-18,21,26. Cases were eliminated if they were of
periosteal origin12,24, had a possible soft-tissue origin7,22,23,25, had
an unclear histologic diagnosis11, were not clinically detailed or
illustrated15,27, or were reported more than once6,7,14,18.
Of the thirty-two cases of skeletal myxoid chondrosarcoma that were included7-10,13,14,16-18,21,26, sixteen were in male
patients, fourteen were in female patients, and two had no data
on sex. The age at the time of diagnosis ranged from nine to
seventy years, with a mean of forty-two years. The femur was the
most common site of involvement, accounting for nine cases
(28%). Six tumors (19%) occurred in the pelvis, and five tumors
(16%) occurred in the foot. Only one case (3%) occurred in the
hand8.
Immunostaining results were reported for only five previous cases17,18,21,26. Tumor cell reactivity for S-100 was positive in
five of five cases (100%) but with variable intensity, and vimentin
was strongly positive in two of two cases (100%). Cytokeratin and
epithelial membrane antigen were absent in all tumors tested.
Treatment was described for twenty-nine of the thirtytwo patients7-10,14,16-18,21,26. Surgical excision, ranging from local
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curettage to limb amputation, was performed in all twentynine patients. Four patients also received radiation therapy and
four, chemotherapy 4,7,21. Follow-up data were available for
twenty-six patients at a mean of forty-nine months (range, six
to 148 months) after diagnosis 7-10,14,16-18,21 . Local recurrence
developed in eleven patients (42%). Metastases developed in
eight patients (31%), six of whom also had local recurrences.
The lung was the most common site of metastasis, seen in six of
the eight patients. Four patients (15%), three of whom had
confirmed metastases, died of the disease.
Only three cases of myxoid chondrosarcoma in the hand
or wrist have been reported with clinical details, and all were
extraskeletal. All three patients were treated with ray resection
and were disease-free at the time of the latest evaluation. Wide
surgical resection remains the most accepted treatment; little
success has been documented with use of chemotherapy and
radiation in controlling myxoid chondrosarcoma tumors28,29.
Myxoid chondrosarcoma is a distinct subtype of chondrosarcoma with several key differences from conventional
chondrosarcoma of bone. First, myxoid chondrosarcoma tumors do not contain substantial amounts of hyaline cartilage or
mineralized matrix, traits characteristic of conventional chondrosarcoma3,26,30. Rather, myxoid chondrosarcoma is composed
of cords and strands of small eosinophilic cells within an extensive myxoid stroma, with a lace-like configuration 1-3,30.
However, myxoid chondrosarcoma can also contain highly
compact, cellular zones lacking a myxoid stroma 3,31 ; foci of
extensively pleomorphic and anaplastic cells32,33; and, as in our
patient, rhabdoid cells7,21,33,34.
Second, myxoid chondrosarcoma has characteristic immunohistochemical properties. The myxoid stroma of myxoid
chondrosarcoma contains sulfated acid mucopolysaccharides,
demonstrated by strong alcian blue staining resistant to hyaluronidase pretreatment, and by metachromatic staining with
toluidine blue2,3,12,14,16,35. Extraskeletal myxoid chondrosarcoma
tumors have shown strong reactivity for vimentin in almost all
tumors studied1,3. Reactivity for S-100 protein, found in almost
all true cartilaginous neoplasms, is positive only in a minority
of patients with myxoid chondrosarcoma. In our review of
previous series of extraskeletal myxoid chondrosarcoma, only
seventy-two (43%) of 169 tumors were positive for S-100, and
this reactivity was typically focal and weak7,18,34,36-39. Also, immunostaining for epithelial differentiation was rarely positive;
only fourteen (11%) of 123 tumors showed epithelial membrane antigen reactivity18,34,36-39, and just four (3%) of 157 were
reactive for cytokeratin36-39. Cases of myxoid chondrosarcoma
have also been reported with positive staining for neuronspecific enolase, chromogranin, and synaptophysin; all of these
are characteristic of tumors with a neuroendocrine lineage and
suggest a separate histogenesis from conventional chondrosarcoma37-42. In our patient, the immunostaining results
showed strong and diffuse reactivity for vimentin, neuronspecific enolase, chromogranin, and synaptophysin; weak and
focal reactivity for S-100 protein; and absent epithelial membrane antigen and cytokeratin reactivity. This is entirely consistent with a diagnosis of myxoid chondrosarcoma.
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Third, myxoid chondrosarcoma has unique genetic
markers that differentiate it from conventional chondrosarcoma. Extraskeletal myxoid chondrosarcoma tumors demonstrate one of several nonrandom reciprocal chromosomal
translocations in at least 80% of cases9,43-48. The most common
of these, t(9;22)(q22-31;q12), accounts for approximately 75%
of the positive cases4,33 and fuses the EWS gene (22q12) with the
CHN gene (9q22, also called TEC, NOR1, or MINOR)4,49.
The hybridization method used in our patient established
the presence of the EWS-containing chromosomal translocation (22q12) but did not indicate the associated fusion partner.
Although the EWS translocation is also found in a variety of
other tumor types, including Ewing sarcoma-primitive neuroectodermal tumor, clear cell sarcoma, desmoplastic small-cell
tumor, myxoid liposarcoma, and angiomatoid fibrous histiocytoma, these are easily distinguished from myxoid chondrosarcoma by their routine histomorphologic and histochemical
characteristics. In our patient, the EWS translocation is consistent with the most common translocation seen in cases of extraskeletal myxoid chondrosarcoma, t(9;22) EWS-CHN.
Despite the histologic similarity between extraskeletal
and skeletal myxoid chondrosarcoma tumors, some authors
believe them to be separate entities primarily because of the
absence of a chromosomal translocation in the six cases of
skeletal myxoid chondrosarcoma examined6,7. Rather, skeletal
myxoid chondrosarcoma has been viewed as a variant of conventional chondrosarcoma with prominent myxoid degeneration 4,7 . One possible, and controversial, exception to this
involves the report by Gill et al. of a myxoid chondrosarcoma
tumor that demonstrated the t(9;22) translocation involving
the scapula of a sixty-six-year-old man19. On the basis of similar
clinical details and a shared source institution, we believe
that this is the same patient described by Sciot et al. and by
Kilpatrick et al20,21. Because of the reported marked destruction
of the scapula with an extensive soft-tissue component in this
case, we believe, as do others7, that there is doubt concerning
the origin of this particular tumor in bone versus soft tissue.
Unfortunately, no radiographs were provided. Thus, prior to
the case of our patient, no definitive intraosseous myxoid
chondrosarcoma tumor has been described with the EWS
translocation.
We considered the possibility that the tumor in our patient might represent a metastasis from an extraskeletal primary
myxoid chondrosarcoma tumor. In 2007, Ehara et al. documented the cases of four patients in whom soft-tissue myxoid
chondrosarcoma tumors had metastasized to bone, and these
metastases were both local and distant50. However, we did not
identify a soft-tissue primary tumor on physical examination
or on subsequent metastatic work-up. Also, although extraskeletal myxoid chondrosarcoma can secondarily involve bone
by direct extension, the tumor in our case clearly originated
within bone, on the basis of the operative, radiographic, and
pathologic findings12,18,31,51.
Extensive myxoid degeneration in an otherwise conventional osseous chondrosarcoma may yield biopsy tissue that is
indistinguishable from that of true skeletal myxoid chondro-
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sarcoma. However, the usual radiographic pattern of abundant
cartilaginous matrix with calcification in conventional chondrosarcoma is in contrast to the osteolytic pattern typically seen
in myxoid chondrosarcoma3,7,52. Additionally, conventional chondrosarcoma with myxoid change contains abundant malignantappearing hyaline cartilage, has strong and diffuse S-100
protein reactivity, lacks neuroendocrine differentiation, and
possesses no characteristic chromosomal translocations52,53.
Our difficulty in accurately diagnosing this tumor prior to
initial resection was based on the relatively nonspecific appearance
of the lesion on radiographs and magnetic resonance imaging
(MRI) and the rarity of all types of chondrosarcoma in the finger
phalanges54,55. In retrospect, rather than an intralesional excision,
an incisional biopsy with staged definitive treatment would have
been ideal. This difficulty in preoperative diagnosis was also encountered by Kwon et al., who performed a needle biopsy of a
calcaneal myxoid chondrosarcoma after MRI led to a presumptive diagnosis of benign chondromyxoid fibroma26. While the
imaging findings in our patient were consistent with previous
descriptions of skeletal myxoid chondrosarcoma—namely, a lytic
lesion without internal calcifications and with cortical expansion
and endosteal scalloping—many of these features also characterize finger enchondromas7,24,26. With MRI, skeletal myxoid
chondrosarcoma demonstrates a lobulated appearance with intense enhancement after injection of gadolinium contrast me-
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dium. In the absence of contrast, T2 signal within the tumor is
more intense than T1 signal24,26,37.
To our knowledge, the case of our patient is the first
definitive example of a primary intraosseous myxoid chondrosarcoma tumor containing the same chromosomal translocation as found in its extraosseous counterpart. On the basis
of this case, we believe there is no essential difference between
skeletal and extraskeletal myxoid chondrosarcoma tumors in
terms of their cytomorphology, immunohistochemical features, and genetic character, and they should be considered as a
single tumor type. n
NOTE: The authors thank Arie Perry, MD, Department of Pathology, Washington University School of
Medicine, for his assistance with the in situ hybridization study.
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